All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Caroline Besson, Université de Paris, Paris, FR. We asked, How does COVID-19 impact patients with lymphoma receiving B-cell-depleting immunotherapy?
How does COVID-19 impact patients with lymphoma receiving B-cell-depleting immunotherapy?
In this video, Besson discusses the outcomes of a trial looking at patients with lymphoma and COVID-19 infection, including duration of hospitalization, mortality rates, and comorbidities.
Management of COVID-19 outbreak on transplant wards
An article based on a webinar arranged by the EBMT and ASTCT titled “Strategies to prevent and handle outbreak of COVID-19 on transplant wards”.
Predictive factors of mortality in patients with hematological malignancies diagnosed with COVID-19
During this COVID-19 pandemic, patients with hematological malignancies—who are immunocompromised because of the cancer itself, immunosuppressive...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox